Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2017 2
2018 1
2019 1
2020 2
2021 2
2022 2
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Rubini NPM, Pires MC, Rossi AB, Zhang A, Chen Z, Levit NA, Chao J, Shumel B, Bégo-Le Bagousse G. Silverberg JI, et al. Among authors: bego le bagousse g. J Allergy Clin Immunol Pract. 2022 May;10(5):1279-1285.e1. doi: 10.1016/j.jaip.2021.11.034. Epub 2022 Jan 12. J Allergy Clin Immunol Pract. 2022. PMID: 35032695 Free article. Clinical Trial.
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Silverberg JI, Simpson EL, Boguniewicz M, De Bruin-Weller MS, Foley P, Kataoka Y, Bégo-Le-Bagousse G, Chen Z, Shumel B, Chao J, Rossi AB. Silverberg JI, et al. Among authors: bego le bagousse g. Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307. Acta Derm Venereol. 2021. PMID: 34618162 Free PMC article.
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Silverberg JI, Lynde CW, Abuabara K, Patruno C, de Benedetto A, Zhang H, Thomas RB, Bégo-Le-Bagousse G, Khokhar FA, Vakil J, Marco AR, Levit NA. Silverberg JI, et al. Among authors: bego le bagousse g. Am J Clin Dermatol. 2023 Jul;24(4):673. doi: 10.1007/s40257-023-00784-6. Epub 2023 May 17. Am J Clin Dermatol. 2023. PMID: 37193879 Free PMC article. No abstract available.
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.
Deleuran M, Marcoux D, Bruin-Weller MS, Irvine AD, Baselga E, Ahn K, Castro AP, Bansal A, Chao J, Bégo-Le-Bagousse G, Rossi AB. Deleuran M, et al. Among authors: bego le bagousse g. Acta Derm Venereol. 2021 Jul 15;101(7):adv00504. doi: 10.2340/00015555-3848. Acta Derm Venereol. 2021. PMID: 34043020 Free PMC article. Clinical Trial. No abstract available.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L. O'Connor PW, et al. Among authors: bego le bagousse g. J Neurol. 2013 Oct;260(10):2472-80. doi: 10.1007/s00415-013-6979-y. Epub 2013 Jul 14. J Neurol. 2013. PMID: 23852658 Free PMC article. Clinical Trial.
Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials.
de Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C, Eckert L, Gadkari A, Bégo-Le Bagousse G. de Bruin-Weller M, et al. Among authors: bego le bagousse g. J Am Acad Dermatol. 2020 Nov;83(5):1499-1501. doi: 10.1016/j.jaad.2020.05.142. Epub 2020 Jun 3. J Am Acad Dermatol. 2020. PMID: 32504724 Free article. No abstract available.
15 results